Hinova Pharmaceuticals released its semi-annual performance, with a net loss attributable to the parent company of 61.85 million yuan
Hinova released its 2025 semi-annual report, with revenue of 13.17 million yuan, a year-on-year increase of 11,899.08%. The net loss attributable to the parent company was 61.85 million yuan, and the net profit excluding non-recurring items was a loss of 73.01 million yuan, with basic earnings per share of -0.62 yuan. The significant revenue growth was mainly due to the launch of the new drug deuterated enzalutamide soft capsules, with sales revenue reaching 13.0688 million yuan
According to the Zhitong Finance APP, Hinova (688302.SH) disclosed its semi-annual report for 2025, showing that the company achieved revenue of 13.17 million yuan during the reporting period, a year-on-year increase of 11,899.08%; the net loss attributable to shareholders of the listed company was 61.85 million yuan; the net profit excluding non-recurring items was a loss of 73.01 million yuan; basic earnings per share were -0.62 yuan.
During the reporting period, the company achieved significant growth in operating revenue, mainly due to the approval of its first Class 1 new drug, deuterated enzalutamide soft capsules (project number: HC-1119), for market launch on May 29, 2025, generating drug sales revenue of 13.0688 million yuan, while the operating revenue in the same period last year was only a small amount from material sales
